National Institutes of Health Office of Science Policy

Applied UV Inc. Secures New Patent Approval From the USPTO for Interchangeable Drain Disinfecting Device Undergoing Validation at Mt Sinai Hospital

Retrieved on: 
Thursday, November 2, 2023
Puro, Building, Patent, National Institutes of Health Office of Science Policy, Hospital, Federation, Infection, United States Patent and Trademark Office, Disinfectant, U.S. federal government response to the COVID-19 pandemic, Fighter, The Fighter, Purdue University, Partnership, Food security, Health, Safety, Johnson Controls, Hygiene, Food storage, Sewage treatment, Plumbing, 3D printing, Heating, ventilation, and air conditioning, Medical device, UV, HVAC

New Patent Approval - Interchangeable Drain Disinfecting Device:

Key Points: 
  • New Patent Approval - Interchangeable Drain Disinfecting Device:
    The Company’s patent for this innovative device optimizes UV source irradiation to effectively disinfect drain systems, contributing to enhanced hygiene and safety.
  • This strategic development aligns with Applied UV Inc.'s commitment to providing cutting-edge solutions for healthier living and working environments.
  • Current Testing at Mt Sinai University Hospital, NYC:
    Applied UV’s Interchangeable Drain Disinfecting Device is currently undergoing rigorous testing at the esteemed Mt Sinai Hospital System in New York City.
  • For more information about these recent patent approvals and Applied UV Inc.'s innovative solutions, please visit our website and explore the press release section at https://www.applieduvinc.com .

Catalyzing Global Access: Innovations in Vein Health

Retrieved on: 
Tuesday, October 3, 2023
Partnership, Hope, National Institute of Standards and Technology, Patient, Love, Ecosystem, Health, Medtech, Regulation of tobacco by the U.S. Food and Drug Administration, Food, National Institutes of Health Office of Science Policy, American Medical Group Association, Pharmaceutical industry

Smile Medical Group joined forces on Monday, September 25, 2023, to commemorate a significant milestone in their partnership for the advancement of vein healthcare innovations through the Global CHIVA Program.

Key Points: 
  • Smile Medical Group joined forces on Monday, September 25, 2023, to commemorate a significant milestone in their partnership for the advancement of vein healthcare innovations through the Global CHIVA Program.
  • His remarks underscored the county's commitment to fostering global collaborations that improve the well-being of the community.
  • The Global CHIVA Program has been a labor of love, driven by our shared vision of transforming vein healthcare.
  • Smile Medical Group and Inteleos enters its third year, the commitment to innovation, quality patient care, and the pursuit of excellence remains unwavering even through the global pandemic.

Life Science Industry in California Generates $413.7 Billion Annually

Retrieved on: 
Tuesday, June 6, 2023
University, Biotechnology, Education, Health, Pharmaceutical, Other Science, Medical Devices, Research, Genetics, Science, Clinical Trials, Employment, NIH, National Institutes of Health Office of Science Policy, Video game, Renewable energy, Pharmaceutical industry

Biocom California, the association representing the California life science industry, today released a new report showing California’s life science industry directly provides more than 460,000 jobs in the state and generates $413.7 billion in total business output.

Key Points: 
  • Biocom California, the association representing the California life science industry, today released a new report showing California’s life science industry directly provides more than 460,000 jobs in the state and generates $413.7 billion in total business output.
  • Biocom California’s 2023 Economic Impact Report outlines these and other key findings about the state’s life science industry, including information on economic, demographic, investment and industry performance data.
  • “California continues to be the leading innovation hub for the life science industry, and the 2023 Economic Impact Report provides key data on the impact it has on the state and regional economies,” said Joe Panetta, president and CEO of Biocom California.
  • Life science organizations in California expanded employment by 6.0% in 2022, outpacing all other industries in California (4.2%) as well as the U.S. overall (3.5%).

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

Retrieved on: 
Thursday, March 16, 2023
Research, Smoking, International, Webcast, 1836 U.S. Patent Office fire, U.S.–Canada Team Tournament (Go), NIH, Patent, Patient, Smoker, Nicotine, Cytisine, Safety, Annual, Clinical trial, National Institutes of Health Office of Science Policy, Pharmaceutical industry, Birth control

Additional findings also demonstrated consistently higher rates of abstinence in subjects who received either 6 or 12-weeks of cytisinicline, compared to placebo.

Key Points: 
  • Additional findings also demonstrated consistently higher rates of abstinence in subjects who received either 6 or 12-weeks of cytisinicline, compared to placebo.
  • Total operating expenses for the fourth quarter and year ended December 31, 2022 were $10.9 million and $40.8 million, respectively.
  • Total net loss for the fourth quarter and year ended December 31, 2022 was $11.2 million and $42.4 million, respectively.
  • To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts .

South Rampart Pharma to Present at 2023 BIO CEO & Investor Conference

Retrieved on: 
Tuesday, January 31, 2023
Financial endowment, Conference, Pain, Entrepreneurship, CFO, Joint Medical Service (Germany), National Directorate for Personal Data Protection, EST, Biotechnology Innovation Organization, Research, Therapy, NIH, FACS, BIO, National Institutes of Health Office of Science Policy, Clinical trial, Pharmaceutical industry, MD, Policy

NEW ORLEANS, Jan. 31, 2023 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.

Key Points: 
  • Pain Foundation
    NEW ORLEANS, Jan. 31, 2023 /PRNewswire/ -- South Rampart Pharma ("South Rampart" or the "Company"), a clinical-stage life science company advancing innovative non-opioid medications for the treatment of pain, today announced that Hernan Bazan, MD, FACS, CEO and Co-Founder of South Rampart Pharma and the Endowed John Ochsner Professor of Cardiovascular Innovation at the Ochsner Clinic, will present at the BIO CEO & Investor Conference on Monday, February 6.
  • Dr. Bazan's presentation will highlight the recent company developments on its novel non-opioid lead asset, ongoing pipeline progress, clinical trial updates and anticipated milestones.
  • Dr. Bazan and Josh Blacher, CFO, will be available for one-on-one investor meetings with registered conference attendees.
  • Meetings can be scheduled via the BIO One-on-One Partnering system: https://www.bio.org/events/bio-ceo-investor-conference/bio-one-one-partn...

Sitero Launches Biosafety Advisory Board, Naming Renowned Experts to Provide Guidance on Biosafety Compliance

Retrieved on: 
Tuesday, January 10, 2023
Government, American College, Associate, Research, CDC, Plum Island Animal Disease Center, Merck, COVID-19, Laboratory, Federation, NBAF, IBC, CBSP, Growth, Select agent, Colorado State University, American Society for Clinical Laboratory Science, Environment, PPE, Biorisk, N95, National Institutes of Health Office of Science Policy, University, ABSA, Duke University School of Medicine, Biomedicine, RBP, NIH, Biocontainment, Pharmaceutical industry, Medical device, Biosafety, Safety

MIAMI, Jan. 10, 2023 /PRNewswire/ -- Sitero has launched a first-of-its kind Biosafety Advisory Board and named several renowned biosafety experts as inaugural board members.

Key Points: 
  • MIAMI, Jan. 10, 2023 /PRNewswire/ -- Sitero has launched a first-of-its kind Biosafety Advisory Board and named several renowned biosafety experts as inaugural board members.
  • The board will advise Sitero on its biosafety services, helping ensure that the company provides industry-leading support for biosafety compliance.
  • The Sitero Biosafety Advisory board is the latest investment that Sitero is making in their Biosafety and IBC offerings due to their recent and expected continued growth in the space.
  • "Their efforts will be instrumental in delivering best practices in biosafety to inform our work at Sitero and advance the biosafety profession."

Discovery of 119-million-year-old selfish genes in yeast potentially alters our understanding of how parasitic DNA impacts genome evolution

Retrieved on: 
Wednesday, October 19, 2022
National Institute, American Century Companies, Stowers Institute for Medical Research, Biology, Doctor of Philosophy, Thought, Technology, Life, Population, Medical research, Association, Longevity, Perception, NIH, Institute, Multimedia, New, Mutation, Health, National, Spore, Egg, Meiosis, National Institutes of Health Office of Science Policy, Infertility, Genome, Fertility, Cell division, Chromosome, Gene, Human, Agriculture, Pharmaceutical industry, Antibiotics, Science, ELife

Meiotic drivers are thus named as they can acquire the ability to literally "drive" the transmission of their genes throughout a genome, often with negative consequences.

Key Points: 
  • Meiotic drivers are thus named as they can acquire the ability to literally "drive" the transmission of their genes throughout a genome, often with negative consequences.
  • Natural selection in a genome typically rescues a species from selfish genes by favoring genes that suppress, or silence drive, rendering it useless.
  • It also changes the way scientists may look for and identify families of selfish genes in different species, including humans.
  • "Since selfish genes are major drivers of evolution, this new finding opens the door for thinking about how drivers can have persistent, long-term effects on genome evolution."

Philip Morris International Announces Appointment of Two Former U.S. FDA Officials, Highlighting the Company’s Continued Commitment to Smoke-Free Product Science and Regulation

Retrieved on: 
Wednesday, September 14, 2022
Retail, Health, Tobacco, Other Health, Research, Science, Smoke, Center for Tobacco Products, PMI, CTP, U.S. FDA, Policy, NYSE, FDA, Food, Center, Center for Drug Evaluation and Research, Sale, Knowledge, Food and Drug Administration, National Institutes of Health Office of Science Policy, Division, Public policy, Philip Morris International, Industry, Toxicology, Holman, Government, IQOS, Regulation of tobacco by the U.S. Food and Drug Administration, Degenerative disease, List of life sciences, Public health, Tobacco, Solution, Smokeless tobacco, Biochemistry, Doctor of Philosophy, Foreign policy, College Park, Autoimmunity, History of the University of Maryland, College Park, Lung, Inflammation, Smoking, Marketing, CDER, University, Pharmaceutical industry, Management, Science, Research

His wealth of knowledge and experience will be critical to help achieve our ambition of a smoke-free future.

Key Points: 
  • His wealth of knowledge and experience will be critical to help achieve our ambition of a smoke-free future.
  • I also extend my sincere thanks to Jorge Insuasty for his contributions to the function as he moves to oversee Vectura Fertin Pharma full-time.
  • Dr. Chowdhury joins PMI from a U.S.-based biotech company developing inhalation products for rare respiratory diseases, where he was Chief Medical Officer.
  • The investment the company has already made in delivering high-quality science to support its transformation and smoke-free vision is unprecedented.

Color, Broad Institute and Partners LMM selected by NIH as Genome Center for historic 'All of Us' Research Program

Retrieved on: 
Tuesday, September 25, 2018
Science and technology in the United States, Health, Nursing research, MARYLAND, National Institutes of Health, Broad Institute, National Institutes of Health Office of Science Policy

The All of Us Research Program is one of the most ambitious biomedical research efforts ever undertaken in the U.S.

Key Points: 
  • The All of Us Research Program is one of the most ambitious biomedical research efforts ever undertaken in the U.S.
  • The Program will sequence one million or more people across the U.S., with the goal of accelerating health research and enabling individualized prevention, treatment, and care.
  • These analyses will be based on clinical-grade genomic data generated at the Broad Institute, one of the world's leading clinical genomic and health research facilities.
  • "We are honored to be selected by the NIH, along with our exceptional partners at the Broad Institute and Partners LMM, to help implement this groundbreaking research program," said Color CEO Othman Laraki.